Lonza expands bioconjugation in Visp with two additional manufacturing suites
Advertisement
Lonza announced it will invest in additional bioconjugation capabilities in Visp (CH). The expansion will add two multipurpose 1,200L manufacturing suites and manufacturing-related infrastructure to the existing bioconjugation facility in Visp (CH) for launch and commercial supply. The new capacity will generate approximately 200 new jobs and is expected to be operational from 2028.
The new suites will occupy approximately 2,000m2 and double Lonza’s multipurpose capacity for the launch and commercial supply of bioconjugates. The flexible multi-customer suites are designed to run the increasingly complex and variable processes needed to manufacture antibody-drug conjugates (ADCs) and other bioconjugates maturing through the drug pipeline.
The additional bioconjugation suites will support the growth of Lonza’s leading bioconjugation offering, spanning manufacturing for early phase clinical development, large-scale manufacture for launch and commercial supply, and will include drug product filling capability. This investment follows the recently announced customer-dedicated bioconjugation expansion in Visp (CH).
Christian Morello, Vice President, Head of Bioconjugates, Lonza, commented: “We continue to see strong growth in the bioconjugates space as ADCs and other bioconjugated drugs increasingly progress towards commercialization. This investment in our multipurpose commercial bioconjugation capacity addresses the growing market demand, enables us to support the growth of our customers and offers a flexible and integrated service for manufacturing bioconjugates.”
As part of Lonza’s emission reduction strategy, the manufacturing suites follow sustainability design standards for new builds that include energy-efficient water heating systems, air supply and lighting solutions, leading to a significant decrease in carbon footprint compared to traditional design solutions. In addition, technology for improved cytotoxic liquid waste management will reduce waste by up to 90%.
Other news from the department manufacturing
Most read news
More news from our other portals
Last viewed contents
Daiichi Sankyo's investments in cancer drugs are taking shape - From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany
Waldner: Ground-breaking for new powder coating plant
Roche lays the foundation for the diagnostics production of the future in Germany - Investment of more than 600 million euros in a high-tech production center - Roche's largest single investment in Germany to date
ProBioGen expands protein and virus manufacturing to drive continued growth
Enduro Genetics raises €12 million to unlock the future of scalable bioproduction - Patented cell reprogramming technology "addicts" cells to high production and integrates seamlessly into any microbial bioproduction host
Sensirion opens additional production building in Debrecen
Frank Winkler receives the Brain Prize 2025 - The interaction between the nervous system and cancer is increasingly coming into focus
CorTec Welcomes Dr. Frank Desiere as Chief Executive Officer - A Strengthened Leadership Team to Accelerate Growth and Innovation
New Leadership at Andreas Hettich GmbH - After 20 years of successful leadership by the Eberle family, the Hettich Group is entering a new, forward-looking phase
Managing Director Peter Sölkner leaves Vetter - Managing Director Carsten Press takes over the relevant departments
Turning fallen leaves into sustainably made paper - Ukrainian scientist selected as a finalist for the Young Inventors Prize 2024
